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Abstract
In Drosophila, dosage compensation augments X chromosome-linked transcription in males relative to females. This
process is achieved by the Dosage Compensation Complex (DCC), which associates specifically with the male X
chromosome. We previously found that the morphology of this chromosome is sensitive to the amounts of the
heterochromatin-associated protein SU(VAR)3-7. In this study, we examine the impact of change in levels of SU(VAR)3-7 on
dosage compensation. We first demonstrate that the DCC makes the X chromosome a preferential target for
heterochromatic markers. In addition, reduced or increased amounts of SU(VAR)3-7 result in redistribution of the DCC
proteins MSL1 and MSL2, and of Histone 4 acetylation of lysine 16, indicating that a wild-type dose of SU(VAR)3-7 is required
for X-restricted DCC targeting. SU(VAR)3-7 is also involved in the dosage compensated expression of the X-linked white
gene. Finally, we show that absence of maternally provided SU(VAR)3-7 renders dosage compensation toxic in males, and
that global amounts of heterochromatin affect viability of ectopic MSL2-expressing females. Taken together, these results
bring to light a link between heterochromatin and dosage compensation.
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Introduction
Drosophila melanogaster uses two systems of whole chromosome
regulation: dosage compensation mediating the two fold up-
regulation of male X-linked genes and the Painting of Fourth,
POF, regulating the mainly heterochromatic fourth chromosome.
Binding of POF to the fourth chromosome is dependent on the
heterochromatic protein HP1 [1]. POF and HP1 colocalize on
fourth chromosome-linked genes and both are involved in the
global regulation of the fourth chromosome [1,2]. Johansson et al.
(2007) proposed that POF stimulates and HP1 represses genes
expression and that the interdependent binding of these two
proteins precisely tunes output from the fourth chromosome.
Dosage compensation targets the male X chromosome to
correct the unbalance between the unique X chromosome of
males and the two X chromosomes of females. To compensate for
the resulting disparity in X chromosome-linked gene expression,
most X-linked genes in males are hyperactivated. The Dosage
Compensation Complex (DCC) consists of five proteins called the
MSLs for Male Specific Lethal (MSL1, MSL2, MSL3, MLE and
MOF) as well as two non-coding RNAs, roX1 and roX2 (reviewed
in [3,4,5,6]). In males, the expression of MSL2 mediates the
stabilization of the other proteins and the assembly of the DCC
specifically on the X chromosome [7]. This results in an
enrichment of acetylation of histone H4 at lysine 16 (H4K16ac)
on the male X chromosome, due to the MOF protein of the
complex [8,9]. The histone mark could in part explain the
subsequent hypertranscription of X-linked genes in males [10,11].
In females, the Sex-lethal gene turns off the dosage compensation
system by repressing the Msl2 translation [12,13].
One of the most intriguing issues of dosage compensation is the
specific recognition of the male X chromosome by the DCC.
Searches for X chromosomal DNA sequences determining DCC
binding failed to identify a consensus sequence [14,15,16]. Global
mapping of MSL proteins on the X chromosome has demon-
strated that the DCC associates primarily with genes rather than
intergenic regions, displays a 39- bias and correlates with
transcription [14,16,17]. Moreover, the MSL complex is attracted
to genes marked by H3K36 trimethylation, a mark of active
transcription [18]. Furthermore, the levels of DCC proteins MSL1
and MSL2 are critical for correct targeting to the X chromosome
[19]. Over-expression of both msl1 and msl2 results in inappro-
priate MSLs binding to the chromocenter and chromosome 4
[19,20]. MSL2, deleted of its C-terminal part, binds as a complex
with MSL1 to the heterochromatic chromocenter [21]. roX RNAs
are also key components for X chromosome targeting since
roX1roX2 mutants cause relocation of MSLs complex to autosomal
regions and the chromocenter [22,23]. These data reveal an
unpredicted physical association between the MSL complex and
heterochromatic regions.
H4K16 acetylation is not the only chromatin mark distinguish-
ing the Drosophila male X chromosome from the autosomes.
Phosphorylation of H3 at serine 10, catalyzed by JIL-1, is a histone
modification highly enriched on the male X chromosome [24].
The JIL-1 kinase interacts with the DCC and is involved in dosage
compensation of X-linked genes [25,26]. Interestingly, Jil-1
mutant alleles affect both condensation of the male X chromo-
some and expansion of heterochromatic domains, providing
evidence for a dynamic balance between heterochromatin and
euchromatin [27,28]. Other general modulators of chromatin
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chromosome morphology in males [29,30,31]. The NURF
complex and MSL proteins have opposite effects on X
chromosome morphology and on roX transcription [32].
We have discovered previously an intriguing genetic interaction
between the heterochromatic proteins SU(VAR)3-7 and HP1, and
dosage compensation [33]. Su(var)3-7 encodes a protein mainly
associated with pericentromeric heterochromatin and telomeres,
but also with a few euchromatic sites [34,35,36]. Specific binding
to pericentric heterochromatin requires the heterochromatic
protein HP1 [33]. HP1 localizes to heterochromatin through an
interaction with methylated K9 of histone H3 (H3K9me2), a
heterochromatic mark mainly generated by the histone methyl-
transferase SU(VAR)3-9 [37,38,39]. SU(VAR)3-7 interacts genet-
ically and physically with HP1 [35,36] and with SU(VAR)3-9
[38,40]. Su(var)3-7, Su(var)2-5 encoding HP1 and Su(var)3-9 are
modifiers of position effect variegation (PEV), the phenomenon of
gene silencing induced by heterochromatin [34,41,42] (reviewed
in [43,44]). These three genes enhance or suppress the PEV
depending on their doses and thus are considered as encoding
structural components of heterochromatin [45]. Strikingly, the
amounts of SU(VAR)3-7 and HP1 affect male X chromosome
morphology more dramatically than other chromosomes. Re-
duced doses of SU(VAR)3-7 or HP1 result in bloating of the X
chromosome specifically in males [33]. Increased doses of
SU(VAR)3-7 cause the opposite phenotype, a spectacular
condensation of the X chromosome associated with recruitment
of other heterochromatin markers [40]. Some unique feature of
the male X chromosome makes it particularly sensitive to change
in SU(VAR)3-7 amounts. In addition, knock-down of Su(var)3-7
results in reduced male viability leading to a 0.7 male/female ratio
in the progeny of Su(var)3-7 homozygous mutant mothers [40].
The possibility of interaction between activating and repressive
chromatin factors on the male X chromosome led us to analyze
the impact of SU(VAR)3-7 on dosage compensation.
In this study we show that wild-type levels of SU(VAR)3-7 are
required for male X chromosome morphology, X chromosome-
restricted DCC targeting, expression of P(white) transgenes in
males and for coping with increased MSL1 and MSL2 levels. We
provide evidence for interplay between heterochromatin and
dosage compensation in Drosophila.
Results
The DCC Makes the X Chromosome a Preferential Target
for Heterochromatinization by Su(var)3-7 Over-
Expression
An excess of SU(VAR)3-7 induces male and female lethality and
causes spectacular changes in the morphology of polytene
chromosomes [40]. The male X chromosome is always the most
affected chromosome: it becomes highly condensed and shortened
and its characteristic banding pattern is modified. To test whether
the Dosage Compensation Complex is required for the male X
chromosome phenotypes, we over-expressed Su(var)3-7 in a
mutant for the DCC and we examined the morphology of the
X chromosome (Figure 1). Homozygous mutants in mle, the gene
encoding the RNA helicase component of the DCC, do not
compensate for dose and die at the third-instar larval stage, late
enough to permit examination of polytene chromosomes [46,47].
The combination of mle
1 with a transgene over-expressing Su(var)3-
7 (P[HA: SuvarFL4D] [48]), results in an almost normal male X
chromosome morphology whereas brothers in the same progeny
heterozygous for the mle
1 mutation still display strong condensa-
tion of the X chromosome (Figure 1A). Thus, the condensation
process of the male X chromosome in presence of an excess of
SU(VAR)3-7 requires the Dosage Compensation Complex. We
had shown previously that the male X chromosome condensation
coincided with association of SU(VAR)3-7 all along the X
chromosome and recruitment of the heterochromatic proteins
HP1 and H3K9me2 [40]. To test whether the enrichment of
heterochromatic markers on the male X chromosome requires the
presence of the DCC, we performed immunostaining on male
larvae expressing the Su(var)3-7 transgene together with the mle
1
mutation. In homozygous mle
1 larvae over-expressing Su(var)3-7,
SU(VAR)3-7, HP1 and H3K9me2 enrichment on the male X
chromosome is lost in contrast to the heterozygous mle brothers of
the same cross (not shown, and Figure 1B). We conclude that
association of the DCC on the X chromosome is required to make
the X chromosome a preferential target for heterochromatic
markers in a context of high levels of SU(VAR)3-7.
Then, to test whether the DCC is not only necessary but also
sufficient for the altered morphology of the X chromosome, we
examined X polytene chromosomes of females expressing the
Su(var)3-7 transgene and the DCC (Figure 2). Dosage compen-
sation in females was artificially induced by a transgene
expressing MSL2 under the control of the hsp83 promoter [7].
The expression of msl-2 in females over-expressing Su(var)3-7
causes the X chromosomes to condense as typically seen only in
males over-expressing Su(var)3-7 (Figure 2A). Furthermore,
assembly of the DCC on the X chromosomes in these females
leads to an enrichment of SU(VAR)3-7 binding on the X
chromosomes, but also of HP1 and H3K9me2: the heterochro-
matic markers enrichment on the X chromosomes is more or less
abundant according to the strength of the heat-shock inducing
expression of Su(var)3-7 (Figure 2 B, 2C, and not shown). This X
chromosomes coating by heterochromatic markers is never
observed in wild type females (not shown and [40]). The Dosage
Compensation Complex is therefore not only necessary but also
sufficient to allow the massive recruitment of heterochromatic
proteins on the X chromosomes induced by high levels of
SU(VAR)3-7.
Author Summary
In Drosophila, females have two X chromosomes and males
only one. The difference in the dose of X-associated genes
is compensated by male-specific protein machinery, the
Dosage Compensation Complex (DCC), which augments
the activity of genes of the single male X. We report that
the specific targeting of the DCC on the male X
chromosome depends critically on the correct dose of the
SU(VAR)3-7 protein. This protein was previously known to
associate with condensed and silenced regions of the
chromosomes called heterochromatin by contrast with the
active form of chromatin called euchromatin. Loss of
SU(VAR)3-7 in males causes displacement of the DCC to
heterochromatin and bloating of the X chromosome. In
contrast, excess of SU(VAR)3-7 leads to a delocalization of
the DCC to other chromosomes and to massive shrinking of
the X chromosome. We show that SU(VAR)3-7 is involved in
the dosage compensated expression of the X-linked white
gene and in the viability of dosage compensated flies.
Altogether, these results bring to light a link between
silencing mechanisms of heterochromatin and mechanisms
controlling the balance of sex-chromosome activity (dos-
age compensation). This opens new perspectives on how
complexes that control the global chromosome organisa-
tion impact the fine tuning of gene expression.
SU(VAR)3-7 and Dosage Compensation
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not colocalize with the heterochromatic proteins: some regions of
the X chromosome enriched for SU(VAR)3-7 and HP1 are almost
devoid of MSLs and inversely (Figure 2D). The dosage
compensation complex renders the X chromosomes especially
attractive to the SU(VAR)3-7/HP1 complex, when in large
amounts, but its binding pattern differs from that of MSLs.
A Lack of Maternal SU(VAR)3-7 Protein Reduces White
Expression Specifically in Males
To test whether SU(VAR)3-7 is recruited by the DCC, we
examined whether a P[w
+GMroX1] transgene, known to recruit the
DCC when inserted on an autosome [49], is able to attract
SU(VAR)3-7 and HP1 at its insertion site. Three P[w
+GMroX1]
insertions(at 85D,69C,79B[50]) weretestedbyimmunostaining on
males salivary gland polytene chromosomes, with antibodies against
MSL2 as a control for efficient DCC assembling at the insertion site
and against SU(VAR)3-7 and HP1 for the creation of a new binding
site at these locations. Although strong MSL2 staining was detected
atthe autosomal site of thethreelines,neitherSU(VAR)3-7norHP1
were detected at these cytological locations (not shown). We
conclude that the DCC binding to the roX1 transgene does not
recruit detectable amounts of SU(VAR)3-7 and HP1 proteins. In
addition, we crossed the transgenic P[w
+GMroX1] males with wild
type females,or females homozygousmutantsfor Su(var)3-7,i no r d e r
to test whether reduced SU(VAR)3-7 amounts modify the extent of
MSLs spreading around the insertion [49]. We did not observe
significant changes of the local MSL spreading in the absence of
maternal SU(VAR)3-7 (not shown). However, we were surprised to
note that the expression of the white gene, a reporter gene within the
transgene, was modified by the absence of maternal SU(VAR)3-7
product in the three lines (Figure 3 and not shown). The well-known
X-linked white gene and its truncated version mini-white retain full
dosage compensation on the X and partial dosage compensation
when transposed to autosomes [51]. Our observation that white
expression is specifically reduced in males in the crosses that lack
maternal SU(VAR)3-7 leads us to conclude that SU(VAR)3-7
specifically regulates white expression in males. This suggests an
implication of SU(VAR)3-7 in dosage compensation.
Figure 1. Severe condensation of the X chromosome by increased Su(var)3-7 expression requires the Dosage Compensation
Complex. Polytene chromosomes from male third instar larvae containing a heat-shock transgene over-expressing Su(var)3-7 (Su(var)3-7
+++)i n
combination with the heterozygous or homozygous mle
1 mutation. A: Orcein staining. B: Immunodetection of HP1 (red) and DNA staining with DAPI.
Larvae were submitted to daily heat-shocks at 35uC before squashing. Arrows indicate the X chromosome.
doi:10.1371/journal.pgen.1000066.g001
SU(VAR)3-7 and Dosage Compensation
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DCC Binding to the X Chromosome
We wondered then whether the wild type dose of SU(VAR)3-7
is required for correct MSLs localization. We have shown that
in hypomorphic Su(var)3-7 mutants, MSLs staining appears
globally unmodified on the bloated X chromosome ([33] and
Figure 4); MSL1, MSL2 and H4K16ac are still present at
hundreds of sites on the male X chromosome and at very few sites
on autosomes. Interestingly, in more severe Su(var)3-7 mutant
conditions, we did detect changes in MSLs localization: in
Su(var)3-7
R2a8 or in Su(var)3-7
9 homozygous mutant larvae raised
at 29uC, MSL1 and MSL2 proteins are clearly visible at the
chromocenter in proportions that are never observed in wild-type
males raised in the same condition (Figure 4 and Figure S1). The
enrichment at pericentromeric heterochromatin is also visible for
H4K16ac in Su(var)3-7 mutant larvae, meaning that the MSL
complex delocalized at heterochromatin is enzymatically active
(Figures 4 and Figure S1). These results show that reducing the
amounts of SU(VAR)3-7 delocalizes the MSLs towards hetero-
chromatin.
Next, we compared MSLs staining in presence of increased
levels of SU(VAR)3-7. In wild-type males, the MSL1 protein
accumulates at hundreds of sites on the X chromosome and is
associated with 5 +/2 1 sites on autosomes (Figure 5). The
number of autosomal sites increases to thirty on polytene
chromosomes from heat-shocked larvae containing one copy of
Figure 2. Presence of the Dosage Compensation Complex is sufficient for the X chromosome condensation resulting from Su(var)3-7
over-expression. Polytene chromosomes from female third instar larvae harbouring the heat-shock transgene over-expressing Su(var)3-7 with
(DCC
ON) or without (DCC
OFF) the transgene expressing MSL2. A: Orcein staining. B and C: Immunodetection of HP1 (red) and SU(VAR)3-7 (green) on
dosage-compensated females over-expressing Su(var)3-7 (B: moderate Su(var)3-7 expression (one daily heat-shock) and C: strong Su(var)3-7
expression (three daily heat-shocks at 35uC)). Arrows indicate the X chromosomes. D: Double immunodetection of MSL2 (green) and HP1 (red) on X
chromosomes in SU(VAR)3-7 excess condition.
doi:10.1371/journal.pgen.1000066.g002
SU(VAR)3-7 and Dosage Compensation
PLoS Genetics | www.plosgenetics.org 4 May 2008 | Volume 4 | Issue 5 | e1000066the Su(var)3-7 transgene. With two copies of the transgene, the
number of autosomal sites reaches a hundred, and MSL1 exhibits
a decreased affinity for the X chromosome (Figure 5). Similar
delocalization on autosomes is visible for MSL2 and H4K16ac
(not shown and Figure 5). This indicates that the complex is
still enzymatically active on autosomes. Staining by MSL1, MSL2
or H4K16ac of the chromocenter and of chromosome 4 is
not detected. For the three proteins, the delocalization on
autosomal sites is proportional to the dose of SU(VAR)3-7. As
controls, absence of heat-shock in the Su(var)3-7 homozygous
transgenic line and heat shock in wild-type did not cause MSLs
nor H4K16ac delocalization (Figure 5 and not shown). In sum, high
levels of SU(VAR)3-7 in males lead to recruitment of heterochro-
matic proteins on the X chromosome and concomitantly to
delocalization of the MSLs on autosomes, suggesting an antagonism
betweenheterochromatinand theDCC.Weconcludethatwild-type
levels of SU(VAR)3-7 are required for X chromosome-restricted
binding of the MSLs.
Mutation of Su(var)3-7 Does Not Regulate the Expression
of Components of the DCC
Phenotypes of MSLs relocation on autosomes or at chromo-
center due to changes in SU(VAR)3-7 levels resemble those due to
changes in levels of the MSLs [19,20]. Su(var)3-7 mutations could
therefore lead to the production of an altered DCC by modifying
expression of genes encoding components of the complex. We first
compared MSL1 and H4K16ac levels in wild-type and Su(var)3-7
mutant third instar larvae by Western blot analysis. We did not
detect changes (not shown). We have also tested by quantitative
reverse-PCR the level of transcription of msl1, msl2, msl3, mof, mle,
roX1 and roX2 genes in wild-type and Su(var)3-7 male mutant
larvae. We did not detect either significant changes in the levels of
transcription of any of these genes (Figure 6). This indicates that
SU(VAR)3-7 does not regulate directly the expression of dosage
compensation genes, but rather acts at the level of the X
chromosome chromatin conformation.
Figure 3. Lack of SU(VAR)3-7 maternal product decreases mini-
white expression in males. Mini-white expression at 25uC in eyes of
P[w
+GMroX1] adult flies harbouring the transgene at cytological
location 69C [50]. Males and females are hemizygous for the
P[w
+GMroX1]69C insertion and are issued either from (A) wild type
w
1118 mothers or (B) homozygous Su(var)3-7
R2a8 females. The lack of
maternal SU(VAR)3-7 product represses white expression in the ventral
part of the eyes in males but not in females. Flies were observed five
days after hatching.
doi:10.1371/journal.pgen.1000066.g003
Figure 4. The Dosage Compensation Complex is delocalized to
the chromocenter of Su(var)3-7 mutant polytene chromosomes.
Immunodetection of MSL1 and MSL2 or H4K16ac on wild-type males
(WT) or Su(var)3-7
9/9 males raised at 29uC( Su(var)3-7
2/2). Arrows
indicate the X chromosome and arrowheads show the chromocenter.
Complete chromosomes spreads are shown in Figure S1.
doi:10.1371/journal.pgen.1000066.g004
SU(VAR)3-7 and Dosage Compensation
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Expression Specifically in Males and on the X
Chromosome
We then addressed the question of whether the striking
displacement of the DCC on autosomes in presence of an excess
of SU(VAR)3-7 modifies the level of expression of the dosage-
compensated white gene when located either on the X chromo-
some or on autosomes. The white gene harboured by P transgenes
can indeed easily be moved to different places in the genome while
conserving its dosage compensated expression [51]. white expres-
sion was monitored by the levels of eye pigments. Females
homozygous for a P(mini-white) transgene (described in Materials
and Methods) were crossed either to wild type males or to males
harbouring the heat-shock transgene over-expressing Su(var)3-7.
F1 progeny from both crosses was submitted to daily heat-shocks
at 35uC from third instar larval stage to adulthood. We tested 12
lines harbouring the P(mini-white) transgene: six out of twelve
contain a transgene on the X chromosome, and in the six others
the transgene is on an autosome.
Interestingly, for none of the six lines containing the P(mini-
white) on autosomes was eye colour modified in male or female by
increased Su(var)3-7 expression compared to wild type dose of
SU(VAR)3-7 (an example is given in Figure 7). In contrast, for five
Figure 5. The Dosage Compensation Complex is delocalized to autosomal sites on polytene chromosomes over-expressing
Su(var)3-7.A :MSL1 immunodetection on chromosomes harbouring zero (WT), one (Su(var)3-7
+++/+) or two copies (Su(var)3-7
+++/Su(var)3-7
+++)o f
the heat-shock transgene expressing Su(var)3-7. Male larvae were submitted to daily heat-shocks at 35uC before squashing. Arrows indicate the X
chromosomes. B: H4K16ac immunodetection on chromosomes of wild type males or males harbouring two copies of the heat-shock transgene over-
expressing Su(var)3-7 (Su(var)3-7
+++/Su(var)3-7
+++). Male larvae were submitted to daily heat-shocks at 35uC before squashing.
doi:10.1371/journal.pgen.1000066.g005
SU(VAR)3-7 and Dosage Compensation
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F1 males displayed lighter eyes in presence of over-expressed
Su(var)3-7 than in wild-type context. On the other hand, female
eye colour from these crosses did not change with the dose of
SU(VAR)3-7 (Figure 7). As control, we verified that repression of
white gene never occurs in not heat-shocked crosses nor in crosses
with wild-type dose of SU(VAR)3-7 submitted to daily heat-
shocks (not shown and Figure 7). As for the sixth P(mini-white)
line on the X, overproduction of SU(VAR)3-7 in this line killed
the males, whereas females were perfectly viable. This
unexplained male lethality prevented us to conclude on the effect
of over-expressing Su(var)3-7 on male eye colour. In sum, these
data show that an increased dose of SU(VAR)3-7 reduces
specifically in males the level of expression of the dosage
compensated white gene, when and only when this gene is on the
X chromosome.
The remarkable effect of SU(VAR)3-7 on the dosage compen-
sated white gene led us to wonder whether SU(VAR)3-7 is required
for dosage compensation of other X-linked genes. Expression of
seven X-linked genes and two autosomal genes were analyzed by
quantitative RT-PCR in third instar larvae of wild type and
Su(var)3-7 null mutant male. We analyzed transcripts levels of the
seven dosage-compensated genes arm, BR-C, CG14804, dspt6, Gs2,
Pgd, mRpL16 and of two autosomal genes, RNApolII and tubulin a.
The levels of transcripts were normalized to efg1 and gapdh
autosomal genes as internal standard. We did not detect significant
modifications of expression of these X-linked genes in Su(var)3-7
mutant males larvae compared to autosomal genes (Figure S2).
These results indicate that the lack of SU(VAR)3-7 does not
significantly modify the transcription level of a set of X-linked
genes.
SU(VAR)3-7 Is Required for Male Viability when MSLs Are
Over-Produced
To investigate further the implication of SU(VAR)3-7 on dosage
compensation, we wondered whether the amounts of SU(VAR)3-7
have an impact on male viability. Indeed, knock-down of Su(var)3-
7 results in significantly more lethality in males than in females
[52]. It is however difficult to compare male and female viability as
they differ by many factors as sex differentiation, dosage
compensation, heterochromatin amounts, etc. We therefore
examined viability among males with modified DCC activities.
In a Su(var)3-7 mutant background, we compared the viability of
males in presence of different amounts of MSLs proteins by using
transgenes expressing MSL1 and MSL2 under the control of the
hsp83 promoter [7,53]: The transgenes do not affect the viability
of otherwise wild-type males (Table 1). But the absence of
maternal SU(VAR)3-7 kills the males harbouring the transgenes:
homozygous Su(var)3-7
R2a8 females crossed with transgenic
(H83MSL1-H83MSL2) males produce only 6% of male adult
progeny harbouring the transgenes compared to 48% if the
mothers are heterozygous for a Su(var)3-7 mutation. However,
with mothers homozygous mutant for another heterochromatic
component, the SU(VAR)3-9 histone-methyl-transferase, we
found no effect on the viability of males. The absence of maternal
SU(VAR)3-7 product specifically renders increased MSL1 and
MSL2 expression toxic to males.
Global Amounts of Heterochromatin Affect Viability of
Females Engineered To Expressing msl2
In Drosophila, the Y chromosome is 20 Mbases long and is
made almost entirely of heterochromatin [54]. To test whether the
Figure 6. Su(var)3-7 mutation does not modify transcript accumulation of DCC components. Histograms display quantitative RT-PCR
analysis of transcript amounts in Su(var)3-7
R2a8 and wild-type male third instar larvae. Triplicate PCRs were performed on triplicates of samples, and
the results obtained for each tested genes were normalized with four control genes (Materials and Methods). Bars represent standard deviation from
the mean.
doi:10.1371/journal.pgen.1000066.g006
SU(VAR)3-7 and Dosage Compensation
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activity, we crossed either wild-type females or females engineered
to expressing msl2 by carrying the msl2 transgene (H83MSL2 [7])
to males bearing a compound X-Y chromosome (C(1:Y)yw). These
crosses produce males lacking the Y chromosome (X/0) and
females containing a Y chromosome (XXY). Details of the crosses
and of their offspring are given in Materials and Methods and in
Supporting Information Table S1. In the control crosses, female
viability is slightly modified by the presence of a Y chromosome
(female/male ratio: 0.72) and viability of XX females is not altered
by the presence of the msl2 expressing transgene thanks to a
mutation into the endogenous msl1 gene (female/male ratio 0.96).
However the combination of the msl2 transgene and additional
heterochromatin provided by the extra Y chromosome affects
severely the viability of females (female/male ratio 0.26). The
effect on viability lends weight to a model whereby dosage
compensation is sensitive to heterochromatin.
Discussion
Our work reveals a connection between heterochromatin and
dosage compensation in Drosophila. We determined that
SU(VAR)3-7 is implicated in male X chromosome morphology,
in correct distribution of the DCC, in the expression of the dosage
compensated white gene and in male viability. Figure 8 recapit-
ulates some of the complex interactions between SU(VAR)3-7 and
the DCC and illustrates the ability of heterochromatin/DCC
balance to affecting chromatin conformation and protein distri-
bution. Our results support a model whereby the activating dosage
compensation system in Drosophila is influenced by chromatin
silencing factors.
Male X Chromosome Sensitivity to SU(VAR)3-7
Reduced levels of SU(VAR)3-7 induce bloating of the male X
chromosome, whereas increased levels cause condensation of the
male X chromosome [33,40]. Moreover, at high dose, SU(VAR)3-
7, normally restricted to heterochromatin, invades preferentially
the male X chromosome and, to a lesser extent, the autosomes
[40]. These observations led us to investigate the features
rendering the male X chromosome particularly sensitive to
SU(VAR)3-7. In this paper we have examined the genetic
interaction between a gene essential for dosage compensation,
mle, and Su(var)3-7 on the morphology of the male X chromosome.
Bloating and shrinking of the X chromosome both require the
presence of the DCC, and assembly of the DCC in females is
sufficient to make their X chromosomes preferential targets for
SU(VAR)3-7, when in excess (Figures 1 and 2). The dosage
compensation system is thus responsible for the sensitivity of the
male X chromosome to changes in SU(VAR)3-7 amounts. One
explanation for the X chromosome sensitivity is that increased
levels of H4K16 acetylation induced by the DCC render
chromatin of the male X chromosome more accessible to
chromatin factors and more sensitive to disturbances than other
chromosomes [3,4,55]. We cannot exclude the possibility that
SU(VAR)3-7-induced X chromosome defects are indicators of a
more general effect of the protein on all chromosomes as described
for ISWI: Null mutations in the gene encoding ISWI cause
aberrant morphology of the male X chromosome but not of
autosomes and females X chromosomes [29], but expression of a
very strong dominant negative form of ISWI in vivo leads indeed
to decondensation of all chromosomes in both sexes [56].
Nevertheless other data in our work discussed later favour the
hypothesis whereby X chromosome defects result from a specific
interaction between SU(VAR)3-7 and dosage compensation.
Male X chromosome sensitivity to SU(VAR)3-7 was rather
unexpected, as in a wild-type context, in contrast to over-
expression conditions, we did not detect preferential binding of
SU(VAR)3-7 to the male X chromosome. The absence of
detectable SU(VAR)3-7 enrichment on the male X polytene
chromosome from third instar larvae may be due either to lack of
sensitivity of the immunostaining procedure or to observations
made in inappropriate tissues or development stages. Similar
puzzling observations have been made for HP1, which is not
preferentially seen on the male X polytene chromosomes,
Figure 7. Expression of X-linked mini-white transgenes is
specifically reduced in males by increased Su(var)3-7 expres-
sion. P(mini-white) transgene expression inserted on the X or on
autosomal chromosomes was studied in males (A) and females (B) in
absence (WT) or presence of the heat-shock transgene overexpressing
Su(var)3-7 (Su(var)3-7
+++). The figure displays the eyes of adult flies,
submitted to daily heat-shock during their development, from two
lines: one with the P(mini-white) transgene on the X and the other on
an autosome. All the flies were submitted to the same heat-shock
conditions. Flies were observed five days after hatching.
doi:10.1371/journal.pgen.1000066.g007
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chromosome [33,57,58,59]. In cultured cells however, a moderate
HP1 enrichment was detected with the DamID technique on the
male X chromosome and not on the female X chromosomes [60],
suggesting that HP1 participates in the structure of the male X
chromosome.
Wild-Type Amounts of SU(VAR)3-7 Are Required for X
Chromosome-Restricted Binding of the MSL Proteins
A striking and novel result of this study is that precise wild-type
amounts of the heterochromatic protein SU(VAR)3-7 are required
to restrict MSLs binding to the X chromosome. In Su(var)3-7
mutants, we have observed that the MSL proteins are recruited to
the chromocenter (Figure 4 and Figure S1). Furthermore, when
SU(VAR)3-7 is present in excess, MSLs are massively delocalized
from the X chromosome to many sites on autosomes (Figure 5).
We propose two hypotheses. First, the effect of SU(VAR)3-7 on
the MSLs distribution is indirect and due to the regulation of the
expression of a component of the DCC. Indeed, increased amounts
of MSL1 and MSL2 lead to MSLs binding on autosomes and at
chromocenter [19,20,61], and MSLs delocalization from the X
chromosome to autosomes and chromocenter is detectable in
roX1roX double mutants [22,23]. A careful regulation of MSLs and
roX RNAs concentration is therefore important to restrict DCC
activity to appropriate targets. In addition, increased levels of MSL2,
or of both MSL2 and MSL1, result in a diffuse morphology of the X
chromosome [7,20,53]. This phenotype resembles the bloated X
chromosome of Su(var)3-7 and Su(var)2-5 mutants, suggesting that
the amounts of MSL2 and MSL1 are downregulated by the
heterochromatic proteins. Expression of many euchromatic genes
are under the control of the HP1 protein [62,63,64,65], leading us to
testwhether changes in SU(VAR)3-7amountsmodifythe expression
of roXs, msl1 and msl2 or the stability of MSL1 and MSL2.
Quantitative RTPCR (Figure 6) and Western blots did not detect
significant changes in the amounts of DCC components. In HP1
mutant msl1 transcription is also not affected [66]. These results
speak against the hypothesis of regulation of expression of a DCC
component by a SU(VAR)3-7/HP1 complex.
The second hypothesis is that SU(VAR)3-7 modifies the MSLs
distribution by changing the chromatin state of the X chromosome
and of the pericentric heterochromatin. Changes in chromatin
conformation or epigenetic marks could modify affinity of the
DCC for entry sites [15,67]. Demakova et al. [19] and Dahlsveen
et al. [15] have described numerous entry sites on the X
chromosome, and have suggested a hierarchy of entry sites with
different affinities for the DCC. Even cryptic binding sites on
autosomes and at the chromocenter are recognized by the DCC in
certain conditions. We propose that increasing SU(VAR)3-7
amounts on the X chromosome results in an enrichment of HP1
and H3K9 dimethylation [40], and leads to a more compact
heterochromatic-like structure of the X chromosome which then
blocks access to the high-affinity entry sites. The free DCC, chased
from the X chromosome sites turns toward low-affinity sites
present on autosomes, but not toward those embedded into the
chromocenter. Indeed, cryptic chromocenter sites become more
inaccessible by heterochromatin compaction [40], a phenomenon
also responsible for the enhancement of variegation by increased
SU(VAR)3-7 levels [40]. Inversely, the absence of SU(VAR)3-7
induces a more relaxed chromatin state at the chromocenter [33],
thus increasing affinity of the entry sites embedded into
heterochromatin, and allowing MSLs binding at the chromocen-
ter. Similar recruitments of MSLs at heterochromatin have been
described in the literature in three situations: in roX1roX2 mutants
[22,23], in presence of excess of MSL2 [19] and in C-terminal
truncated MSL2 mutants [21]. This means that cryptic entry sites
present in heterochromatin become more accessible to the MSLs
either in a Su(var)3-7 mutants or if DCC composition is modified.
The explanation of heterochromatin affinity for the MSLs remains
obscure. On the X chromosome, the Su(var)3-7 mutation induces
the bloated morphology resembling that described as a result of
decreased levels of silencing factors as HP1, ISWI and NURF
[29,30,33], or of increased MSLs levels [20]. Our study and others
suggest that male X chromosome morphology depends on the
balance between silencing and activating complexes [2,27,28,32].
The simultaneous existence of the repressive SU(VAR)3-7/HP1
proteins and the MSLs complex may provide a set of potential
interactions that cumulatively regulate dosage compensation [6].
Interplay between SU(VAR)3-7 and Dosage
Compensation
Several arguments support a role for SU(VAR)3-7 in dosage
compensation. Reduced male viability in the progeny of Su(var)3-7
homozygous females is a first argument for a function played by
the protein specifically in males [52]. Our results also show that
wild-type amounts of SU(VAR)3-7 are required to cope with
increased MSL1 and MSL2 levels. In absence of maternal
SU(VAR)3-7 product, the transgenes expressing MSL1 and
MSL2 become toxic to males, whereas no lethality is observed
with wild-type or half amounts of SU(VAR)3-7 (Table 1). This
suggests that SU(VAR)3-7 is required very early in development to
counteract an excess of MSL1 or MSL2 activity. Corroborating
this effect, we determined that the global amount of heterochro-
matin affects the viability of females engineered to expressing msl2.
The presence of the highly heterochromatic Y chromosome kills
half of the females expressing msl2. As proposed by Weiler and
Wakimoto [68,69], the Y chromosome functions as a sink for
heterochromatic factors as SU(VAR)3-7 and HP1 [68,69]. A Y
chromosome added to XX females could sequester heterochro-
Table 1. SU(VAR)3-7 requirement for male viability in excess of MSL1 and MSL2.
Father: F1
H83MSL1-H83MSL2/+ with (+) or without (2) H83MSL1-H83MSL2
X Mother: % Male (2) % Male (+) % Female (2) % Female (+)
wt 51% (525) 49% (499) 100% (561) 0% (0)
Su(var)3-7
R2A8/+ 52% (417) 48% (384) 100% (444) 0% (0)
Su(var)3-7
R2A8/R2A8 94% (336) 6% (21) 100% (564) 0% (0)
Su(var)3-9
17/17 51% (279) 49% (270) 100% (339) 0% (0)
doi:10.1371/journal.pgen.1000066.t001
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compensation. All these data lead to the conclusion that
SU(VAR)3-7 is required for the viability of dosage-compensated
flies. We propose two explanations: Either SU(VAR)3-7 is
required to restrict DCC on the X chromosome, and the lethality
induced by the lack of SU(VAR)3-7 is due to the MSLs ectopic
activity outside of the X chromosome (at heterochromatin), or
SU(VAR)3-7 is required on the dosage compensated X chromo-
some and, in this case, the Su(var)3-7 mutant lethality results from
malfunctioning of the DCC on the X.
To discriminate between these two hypothesis, we examined
expression of X-linked genes in Su(var)3-7 mutants (Figure S2).
Although small changes are visible, the RT-PCR analysis did not
allow us to conclude that the lack of SU(VAR)3-7 affects
significantly the levels of transcripts of seven X-linked genes. If
they exist, changes were indeed expected to be very small. For
MSLs mutations, the magnitude of the decrease is very modest
considering the severe failure of dosage compensation (around 1.5
[10,11]). Taking into account that the Su(var)3-7 mutation induces
only 30% lethality among males, expected changes in transcript
Figure 8. Summary of the interactions between SU(VAR)3-7 and the DCC, and illustration of resulting changes in chromatin
conformation and proteins distribution. Tested genotypes are on the left. DCC
ON refers to wild type males or to ectopic MSL2-expressing
females, DCC
OFF: homozygous mle
1 mutant, 3-7
+++: Su(var)3-7 over-expression context. The drawings compile X chromosome morphological data
and immunostainings of MSLs and SU(VAR)3-7. The set of Drosophila salivary gland polytene chromosomes is schematized and the X chromosome
indicated. Chromocenters aspect are as described in [33] and [40]. Immunostainings are illustrated as follows: The DCC is represented in green and
SU(VAR)3-7 in red. Detailed SU(VAR)3-7 and DCC localization on polytene chromosomes and X chromosome morphology is on the right. ‘‘het’’ stands
for heterochromatin. Major changes in protein distribution are highlighted in colour.
doi:10.1371/journal.pgen.1000066.g008
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transcripts analysis was done in male larvae and some slight
biological variations between our three samples cannot be avoided
though great care was taken on samples homogeneity. Finally,
normalizing to internal autosomal genes RNA could also
introduce a bias [6]. We believe that in our case, quantitative
RT-PCR experiment was not the appropriate method to detect
very small changes of expression.
In consequence, we have used an alternative system to test the
implication of SU(VAR)3-7 on dosage compensation. We have
determined the effect of increased or decreased Su(var)3-7
expression on the dosage compensated expression of the white
gene carried by P transgenes. Strikingly, we observed that lack and
excess of SU(VAR)3-7 decreases the white expression specifically in
males, and never in females (Figures 3 and 7). This is a strong
indication that the wild type dose of SU(VAR)3-7 is required for
correct dosage compensated expression of the white gene.
Interestingly, Su(var)3-7 over-expression affects white expression
when the gene is localized on the X chromosome and not on
autosomes, although white is still partially dosage compensated on
autosomes [51]. This may result from the combination of two
phenomena: On the X chromosome, excess of SU(VAR)3-7
induces preferential enrichment of heterochromatic silencing
proteins and partial loss of MSLs. On autosomes, heterochromatic
proteins recruitment is less visible and, in addition, the MSLs are
massively present [40] (Figure 5). Consequently the dosage
compensation of a P(white) transgene linked to the X chromosome
is more likely to be perturbed by excess of SU(VAR)3-7 than an
autosomal insertion.
In sum, we have revealed in this study a role for SU(VAR)3-7 on
global X chromosome morphology with an impact on the
distribution of MSLs proteins, thus highlighting the contribution of
SU(VAR)3-7 to the intriguing issue of X specific DCC targeting. It
appears also that SU(VAR)3-7 is required for the viability of dosage
compensated flies and the expression of a dosage compensated X-
linked gene, suggesting a puzzling interplay between heterochroma-
tin and the DCC. SU(VAR)3-7 plays a subtle role on dosage
compensation: Flies need SU(VAR)3-7, especially the maternal
protein, for correct dosage compensation but, at the same time,
excessofSU(VAR)3-7hasa negative effectondosagecompensation.
Ourfutureinterestwillfocusonthefascinatingissueofthemolecular
nature of heterochromatin/DCC intersection.
Materials and Methods
Fly Stocks
Su(var)3-7 over-expression: heat-shocks were carried out on
Drosophila melanogaster lines containing the inducible Su(var)3-7
transgene P(HA:SuvarFL) (lines 1A and 4D [48]) and on the yw
67
control line. Egg laying was at 25uC for 24 hours, and larvae were
incubated at 30uC for two days. Three heat-shocks of 30 minutes
at 35uC were then performed each day until adulthood. Su(var)3-7
mutants: we used the null mutant Su(var)3-7
R2a8 [33] raised at
25uC and the hypomorphic Su(var)3-7
9 mutant [52] raised at
29uC. P(mini-white) stocks were kindly provided by D. Pauli. Flies
harbour one P(UASt mini-white) transgene localized at different
locations on the X or on autosomes [70]. The P(UASt mini-white)
transgenes harbor different cDNA sequences that are not
expressed due to the lack of GAL4 drivers.
Fly Crosses
- To test whether reduced SU(VAR)3-7 amounts modify the
extent of MSLs spreading around a P[w
+GMroX1] transgene
insertion [49], we crossed ten transgenic ywroX1
ex6/
Y;P[w
+GMroX1] males (from three lines with insertion at 85D,
69C or 79B kindly provided by R. Kelley [49]) to ten wild type
(w
1118) females or w
1118; Su(var)3-7
R2a8 homozygous females. Male
larvae were collected for immunostaining and male adults were
kept to examine the effect of the lack of maternal SU(VAR)3-7 on
white expression. Eyes of adult flies from several crosses replica
were examined five days after hatching.
- To test the effects of increased SU(VAR)3-7 amounts on white
expression of P(mini-white) transgenes, ten P(mini-white) homozy-
gous females were crossed at 25uC either to wild-type males or to
males harbouring the transgene that over-expresses Su(var)3-7 by
heat-shock induction [48]. Progeny from both crosses was
submitted to daily heat-shocks at 35uC from the third instar larval
stage to adulthood or were kept at 25uC for all development. Eyes
of adult flies from several crosses replica were examined five days
after hatching.
- The genetic crosses shown in Table 1 were realized as follows:
Fifteen w
1118; Su(var)3-7
R2a8 homozygous or heterozygous females
were crossed at 25uC with fifteen w/Y; msl2 cn; H83MSL1-
H83MSL2/+ males. Progeny w; msl2 cn/+; Su(var)3-7
R2a8/+ with
(red eyes) or without (white eyes) the H83MSL1-H83MSL2
transgenes was counted. Dramatic difference in males viability was
observed depending upon whether or not the mother supplied wild
type SU(VAR)3-7 protein in the egg. Similar crosses were done
with wild-type and Su(var)3-9
17 homozygous females.
- To test the effect of an additional Y chromosome in females that
ectopically express MSL2 [7], fifteen wild type (w
1118)f e m a l e so ryw;
msl1/Cyo; P(w
+H83-MSL2)6I/P(w
+H83-MSL2)6I females were
crossed at 25uC either to males bearing a compound X-Y
chromosome (C(1;Y)yw)o rt ow
1118 males. In the F1, all the females
and males were counted without discriminating the presence of the
CyO balancer or of the chromosome II with the endogenous msl1
mutation. In fact 95% the F1 females carry the endogenous msl1
mutation that supports their survival. Crosses were done several
timesandthe percentageofmalesand femalesobtainedineachcross
is given in Supporting Information Table S1.
Staining and Immunostaining of Polytene Chromosomes
Orcein stainings of polytene chromosomes were done as in [33].
Proceduresforimmunostaining were thoseof Plateroet al.,[71]with
the following modifications: fixation and squashing were done in 4%
formaldehyde. Primary antibodies were used at the following
dilutions: 1:10 for anti-SU(VAR)3-7 [35], 1:400 for anti-HP1 (a gift
of Lori Wallrath) and 1:200 for anti-MSL2 and anti-MSL1 (gifts of
M. Kuroda), and for anti-H4K16ac (a gift of Brian Turner). For
immunostaining experiments, two independent Hs-Su(var)3-7 trans-
gene insertions and two independent Su(var)3-7 mutants have been
studiedtoavoidgeneticbackgroundeffect.Foreachstaining,mutant
and wild-type larvae were always treated together; salivary glands
were squashed in the same conditions, incubated with the same
antibodies preparation, and analyzed in same exposure conditions.
Each experiment was done several times.
Real-Time Quantitative PCR
RNA was isolated from 30 male third instar larvae using Trizol
(Invitrogen). After DNase treatment (Ambion DNA free
TM), one
mg of total RNA was used to make cDNA using random hexamers
and the Supercript II reverse transcriptase (Invitrogen). Linear real
time PCR was performed using Power SYBR Green Master Mix
(Applied Biosystems), on a SDS 7900 HT instrument (Applied
Biosystems) with the following parameters: 50uC for two minutes,
95uC for ten minutes, and 45 cycles of 95uC 15 secondes260uC
one minute. Each gene was tested with specific primers designed
using the program Primer Express v 2.0 (Applied Biosystems) with
SU(VAR)3-7 and Dosage Compensation
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on request. Triplicates of samples and triplicates of PCR were
performed and the results obtained for each tested genes were
normalized with two or four control genes treated in parallel
(tubulin a, RP49, RNA pol II, EFG1). Raw Ct values obtained
with SDS 2.2 (Applied Biosystems) were imported in Excel and
normalisation factor and fold changes were calculated using the
GeNorm method [72]. Real-time PCR and data analysis were
performed at the Genomics Platform, NCCR ‘‘Frontiers in
Genetics’’ (http://www.frontiers-in-genetics.org/genomics.htm).
Western Blots
Brains of 20 third instar larvae were dissected in Ringer and
resuspended in SDS lysis buffer (1% SDS, 10 mM EDTA, 50 mM
Tris-HCl, pH 8) [73]. Proteins in samples were dosed using the
BCA
TM Protein Assay Kit (Pierce). Samples (5 mgo r1 0mgo f
proteins) were separated on SDS PAGE and transferred on a
PVDF membrane (Millipore). Membranes were blocked in TBS,
0.1% tween, 5% dry milk or BSA with a-MSL-1 (1/500) a-tubulin
(1/2000) (Sigma T 9026), a-H4K16ac (1/50), a-H3 (1/5000)
(Abcam 1791). Membranes were washed with TBS, 0.1% Tween,
incubated with secondary antibodies coupled to HRP and revealed
by chemiluminescence.
Supporting Information
Figure S1 DCC components distribution on polytene chromo-
somes of Su(var)3-7 mutant. Immunodetection of MSL1 and
MSL2 or H4K16ac on wild-type males (WT) or Su(var)3-7
9/9
males raised at 29uC( Su(var)3-7
2/2). Arrows indicate the X
chromosome and arrowheads show the chromocenter.
Found at: doi:10.1371/journal.pgen.1000066.s001 (3.00 MB TIF)
Figure S2 Dosage compensation of X-linked genes is not
affected in Su(var)3-7 mutants. RNA levels of seven X-linked
genes (arm, BRC, CG14804, dspt6, Gs2, mRpL16, Pgd) and two
autosomal genes (tuba and RNApolII) were analyzed by quantitative
RT-PCR in homozygous Su(var)3-7
R2a8 and wild-type male third
instar larvae. Triplicates of samples as triplicates of PCR were
realized and the results obtained for each tested genes were
normalized with two control genes (Materials and Methods). Bars
represent standard deviation from the mean.
Found at: doi:10.1371/journal.pgen.1000066.s002 (1.00 MB TIF)
Table S1 An extra Y chromosome affects viability of females
engineered to expressing msl2.
Found at: doi:10.1371/journal.pgen.1000066.s003 (0.03 MB
DOC)
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